LM103 after surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if LM103, given after surgery and standard chemotherapy, helps prevent non-small cell lung cancer from coming back. It is for people who have already had chemotherapy or immunotherapy before surgery and whose cancer did not return after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You had surgery for non-small cell lung cancer and received chemotherapy or immunotherapy before surgery.
- Your cancer did not come back after surgery, and there are no known gene mutations (driver mutations) in your tumor.
- You are healthy enough to undergo standard activities (ECOG 0-1) and have good organ function.
- You have not had other cancers in the past 5 years, except for certain treatable ones like early skin or thyroid cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving more immunotherapy after surgery can help people with non-small cell lung cancer who still had some cancer cells left after their first round of immunotherapy and chemotherapy before surgery. It aims to improve outcomes for those whose tumor didn't fully disappear.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial tests a combination of immunotherapy (tislelizumab), a targeted therapy (anlotinib), and standard chemotherapy before and after surgery for people with early-stage but high-risk lung cancer. The goal is to see if this treatment shrinks the tumor, makes surgery more effective, and helps prevent the cancer from coming back.
This Phase 1 study tests LM103 to treat advanced cancers that are not responding to standard treatment. It also looks at whether enough tumor tissue can be collected for immune cell testing, and focuses on safety at first.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests whether giving an experimental drug (SYS6010) together with an immunotherapy (a type of treatment that helps your immune system fight cancer) after surgery can lower the chance of cancer coming back. It's for people with non-small cell lung cancer that was completely removed but didn't respond very well to surgery alone.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.